Wassim Nashabeh of Genentech Joins the Editorial Advisory Board of BioPharm International
Wassim Nashabeh, PhD, the global head of technical regulatory policy and strategy at Genentech, has joined the Editorial Advisory Board of BioPharm International.
Wassim Nashabeh, PhD, the global head of technical regulatory policy and strategy at Genentech, has joined the Editorial Advisory Board of BioPharm International.
Wassim Nashabeh received his PhD in analytical chemistry from Oklahoma State University in 1993, and his post-doctoral fellowship from the Barnett Institute of Chemical and Biological Analysis at Northeastern University, where he developed new approaches for the separation of closely related recombinant protein variants. He joined PerSeptive Biosystems as a senior scientist from 1994–1996, where he codeveloped new schemes for antibody modification with fluorescent and enzymatic labels for use in microfabricated chip-based immunoassays.
In 1996, Nashabeh joined Genentech (A member of the Roche Group) as a scientist, and has since held several positions of increasing responsibilities, most recently global head of technical regulatory policy and strategy for the Roche Pharma Group. His current responsibilities include the development of global innovative regulatory strategies.
Nashabeh is a member of the expert working group for the International Committee on Harmonization representing the BIO organization on quality topics. He also is a member of the Board of Directors of CASSS, co-founder and chair of the International Symposium of CE in the Pharmaceutical and Biotechnology Industries, a permanent committee member of the CMC Strategy Forum conference series, co-founder of the CMC Forum Europe Conference Series, and a member of the program committee for the WCBP conference series.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
